Join Growin Stock Community!

Abivax s.a.ABVX.US Overview

US StockHealthcare
(No presentation for ABVX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABVX AI Insights

ABVX Overall Performance

ABVX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABVX Recent Performance

-3.91%

Abivax s.a.

-3.61%

Avg of Sector

-2.16%

S&P500

ABVX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABVX Key Information

ABVX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ABVX Profile

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Price of ABVX

ABVX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ABVX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1805.67
PB Ratio
15.70
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-6434.06%
Revenue Growth (YoY)
-62.64%
Profit Growth (YoY)
-62.64%
3-Year Revenue Growth
-%
3-Year Profit Growth
94.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1805.67
PB Ratio
15.70
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-6434.06%
Revenue Growth (YoY)
-62.64%
Profit Growth (YoY)
-62.64%
3-Year Revenue Growth
-%
3-Year Profit Growth
94.99%

  • When is ABVX's latest earnings report released?

    The most recent financial report for Abivax s.a. (ABVX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABVX's short-term business performance and financial health. For the latest updates on ABVX's earnings releases, visit this page regularly.

  • How much debt does ABVX have?

    As of the end of the reporting period, Abivax s.a. (ABVX) had total debt of 73.99M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ABVX have?

    At the end of the period, Abivax s.a. (ABVX) held Total Cash and Cash Equivalents of 589.7M, accounting for 0.9 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ABVX go with three margins increasing?

    In the latest report, Abivax s.a. (ABVX) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -3,950.61%%, and net margin of -7,506.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ABVX's profit trajectory and future growth potential.